Cheil Bio Co

Cheil Bio Co Equity

Delisted·Feb 25, 2026

The The Equity of Cheil Bio Co (052670.KQ) as of Nov 17, 2026 is 31.07 B KRW. In the previous year, The Equity was 33.03 B KRW — a change of -5.93% (lower).

Equity

31.07 BKRW

YoY

-5.93%

Last updated:

In 2023, Cheil Bio Co's equity was 31.07 B KRW, a -5.93% increase from the 33.03 B KRW equity in the previous year.

The Cheil Bio Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
34.23 B KRW
Jan 1, 2017
30.41 B KRW
Jan 1, 2018
29.68 B KRW
Jan 1, 2019
31.62 B KRW
Jan 1, 2020
38.20 B KRW
Jan 1, 2021
37.33 B KRW
Jan 1, 2022
33.03 B KRW
Jan 1, 2023
31.07 B KRW
The Cheil Bio Co Equity history
YEAREquityYoY
31.07 BKRW-5.93%
33.03 BKRW-11.52%
37.33 BKRW-2.27%
38.20 BKRW+20.81%
31.62 BKRW+6.52%
29.68 BKRW-2.39%
30.41 BKRW-11.16%
34.23 BKRW+2.65%
33.35 BKRW+93.72%
17.21 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cheil Bio Co Stock analysis

What does Cheil Bio Co do? Cheil Bio Co., Ltd. generates revenue through the production and sale of veterinary products for pigs, cattle, chickens, cows, and aquatic animals. The company offers antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, and diagnostic kits including ELISA test kits, virus test kits, and DNA kits. These products are primarily sold to the domestic market, targeting livestock farmers and veterinary clinics. The firm also provides feed additives as part of its product portfolio. The company's product range includes specialized solutions for cattle, pigs, chickens, pets, and other animals, with a focus on health management and disease prevention. Veterinary clinics and livestock farms form the core customer segments, purchasing antibiotics, vaccines, and diagnostic tools to maintain animal health. The domestic market remains the primary sales channel, with no mention of international distribution. Cheil Bio's offerings are designed to address common health challenges in livestock, such as infections and parasitic infestations, through both preventive and therapeutic products. The inclusion of diagnostic kits like ELISA and DNA tests supports advanced veterinary care, enhancing the company's value proposition for professional animal health providers. Cheil Bio Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cheil Bio Co's Equity

Cheil Bio Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cheil Bio Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cheil Bio Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cheil Bio Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cheil Bio Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cheil Bio Co stock

The Equity of Cheil Bio Co is 31.07 B KRW in 2023.

The Equity of Cheil Bio Co changed from 33.03 B KRW to 31.07 B KRW, representing a -5.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cheil Bio Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cheil Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cheil Bio Co

All Key Metrics — Cheil Bio Co